NYSE:AIM

AIM ImmunoTech Stock Forecast, Price & News

$2.28

0.00 (0.00 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.22

▼

$2.31

50-Day Range

$1.93

▼

$2.38

52-Week Range

$1.60

▼

$4.30

Volume443,981 shs

Average Volume1.92 million shs

Market Capitalization$109.06 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.81

30 days | 90 days | 365 days | Advanced Chart

Receive AIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.

AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus, other respiratory diseases
May 27, 2021 | proactiveinvestors.com

AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
May 26, 2021 | finance.yahoo.com

Head to Head Comparison: AIM ImmunoTech (NYSE:AIM) vs. Orchard Therapeutics (NASDAQ:ORTX)
May 24, 2021 | americanbankingnews.com

AIM ImmunoTech CEO says the firm in ‘solid financial standing’ to move forward rapidly with clinical programs
May 18, 2021 | proactiveinvestors.com

AIM ImmunoTech Provides First Quarter 2021 Business Update
May 18, 2021 | finance.yahoo.com

AIM ImmunoTech (NYSE:AIM) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
May 18, 2021 | americanbankingnews.com

AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
May 3, 2021 | finance.yahoo.com

BRIEF-Aim Immunotech Announces Positive Safety Data In Second Cohort Of Phase 1 Clinical Study Investigating Intranasal Administration Of Ampligen As A Potential Prophylaxis Or ...
April 27, 2021 | msn.com

AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
April 27, 2021 | finance.yahoo.com

AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
April 7, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:AIM
Previous Symbol
CUSIPN/A
CIKN/A
Webaimimmuno.com
Phone352-448-7797
Employees21
Year FoundedN/A

Sales & Book Value

Annual Sales$160,000.00
Price / Sales681.62
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.49 per share
Price / Book1.53

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares47,833,000
Market Cap$109.06 million
Next Earnings Date8/13/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.40 out of 5 stars

Medical Sector

729th out of 2,096 stocks

Biological Products, Except Diagnostic Industry

97th out of 196 stocks

3.5 Analyst's Opinion

Consensus Rating
AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.75, AIM ImmunoTech has a forecasted upside of 64.5% from its current price of $2.28.
Amount of Analyst Coverage
AIM ImmunoTech has received no research coverage in the past 90 days.

3.5 Community Rank

Outperform Votes
AIM ImmunoTech has received 56 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AIM ImmunoTech has received 25 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AIM ImmunoTech has received 69.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AIM ImmunoTech and other stocks. Vote “Outperform” if you believe AIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AIM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AIM ImmunoTech does not currently pay a dividend.
Dividend Growth
AIM ImmunoTech does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of AIM ImmunoTech is held by insiders.
Percentage Held by Institutions
Only 15.67% of the stock of AIM ImmunoTech is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AIM ImmunoTech is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AIM ImmunoTech is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AIM ImmunoTech has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

AIM ImmunoTech (NYSE:AIM) Frequently Asked Questions

Is AIM ImmunoTech a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AIM ImmunoTech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AIM ImmunoTech stock.
View analyst ratings for AIM ImmunoTech or view top-rated stocks.

What stocks does MarketBeat like better than AIM ImmunoTech?

Wall Street analysts have given AIM ImmunoTech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AIM ImmunoTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AIM ImmunoTech's next earnings date?

AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for AIM ImmunoTech.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings data on Tuesday, May, 18th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative net margin of 9,718.49% and a negative trailing twelve-month return on equity of 23.90%.
View AIM ImmunoTech's earnings history.

How has AIM ImmunoTech's stock been impacted by COVID-19 (Coronavirus)?

AIM ImmunoTech's stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AIM shares have decreased by 45.7% and is now trading at $2.28.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AIM?

2 brokerages have issued twelve-month target prices for AIM ImmunoTech's stock. Their forecasts range from $2.00 to $5.50. On average, they anticipate AIM ImmunoTech's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts' price targets for AIM ImmunoTech or view top-rated stocks among Wall Street analysts.

Who are AIM ImmunoTech's key executives?

AIM ImmunoTech's management team includes the following people:

Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 68, Pay $1.52M)
Ms. Ellen M. Lintal, CFO & Chief Accounting Officer (Age 62, Pay $441.99k)
Mr. Peter W. Rodino III, Esq., J.D., COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 70, Pay $681.86k)
Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 75)
Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations Coordinator
Dr. Carol A. Smith, Chief Manufacturing Officer & Deputy Chief Scientific Officer (Age 70)
Julie Mierau, Controller
Dr. Ralph Christopher Cavalli, VP of QC & Manufacturing (Age 63)

Who are some of AIM ImmunoTech's key competitors?

Some companies that are related to AIM ImmunoTech include Autolus Therapeutics (AUTL), AVROBIO (AVRO), Opthea (OPT), SQZ Biotechnologies (SQZ), Adverum Biotechnologies (ADVM), Jounce Therapeutics (JNCE), Fusion Pharmaceuticals (FUSN), Freeline Therapeutics (FRLN), Aptose Biosciences (APTO), Innate Pharma (IPHA), Surface Oncology (SURF), Cardiff Oncology (CRDF), Innate Pharma (IPHYF), Eiger BioPharmaceuticals (EIGR) and INmune Bio (INMB).
View all of AIM's competitors.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (5.24%), BlackRock Inc. (2.05%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.74%), Verition Fund Management LLC (0.23%) and Citadel Advisors LLC (0.22%). Company insiders that own AIM ImmunoTech stock include David R Strayer, Stewart Appelrouth, Thomas K Equels, Wayne S Springate and William M Mitchell.
View institutional ownership trends for AIM ImmunoTech.

Which institutional investors are selling AIM ImmunoTech stock?

AIM stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for AIM ImmunoTech or view top insider-selling stocks.

Which institutional investors are buying AIM ImmunoTech stock?

AIM stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management LLC, Citadel Advisors LLC, HighTower Advisors LLC, GSA Capital Partners LLP, and Verition Fund Management LLC. Company insiders that have bought AIM ImmunoTech stock in the last two years include David R Strayer, Stewart Appelrouth, Thomas K Equels, Wayne S Springate, and William M Mitchell.
View insider buying and selling activity for AIM ImmunoTech or or view top insider-buying stocks.

How do I buy shares of AIM ImmunoTech?

Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $2.28.

How much money does AIM ImmunoTech make?

AIM ImmunoTech has a market capitalization of $109.06 million and generates $160,000.00 in revenue each year.

How many employees does AIM ImmunoTech have?

AIM ImmunoTech employs 21 workers across the globe.

What is AIM ImmunoTech's official website?

The official website for AIM ImmunoTech is aimimmuno.com.

Where are AIM ImmunoTech's headquarters?

AIM ImmunoTech is headquartered at 2117 SW HIGHWAY 484, OCALA FL, 34473.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 352-448-7797 or via email at [email protected]

This page was last updated on 6/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here